Autopsy report · NCT05650567

Study of M5049 in DM and PM Participants (NEPTUNIA)

“Based on interim analyses for futility”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 5 months before it stopped.
• 20 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

EMD Serono Research & Development Institute, Inc.

Sponsor type

Industry

Conditions

Dermatomyositis; Polymyositis

Interventions

M5049 dose; Placebo

Participants

20

Sites

31

Countries

Czechia, Greece, Italy, Poland, Spain, United Kingdom, United States

Trials that died the same way

• Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
  “The result of a pre-planned interim futility analysis” (94% match in meaning)
• Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation
  “Interim futility analysis” (94% match in meaning)
• Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
  “Study futility based on the interim analysis” (89% match in meaning)
• Bivalirudin Infusion for Ventricular Infarction Limitation
  “Futility at the interim analysis.” (87% match in meaning)
• Sevoflurane and Percutaneous Coronary Intervention by Stent
  “interim analysis suggests futility” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.